ND0801 is aimed at treating cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer’s disease, Parkinson’s disease and schizophrenia. ND0801 should be a new alternative to the current standard of care that is associated with various side effects. NeuroDerm’s ND0801’s is covered by a patented reformulation and is designed to be a safe and non-addictive nicotine-based combination drug treatment administered via a transdermal patch.
NeuroDerm is currently testing ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on 45 adult patients. The study is designed to measure the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801.
Interim results from 30 patients enrolled so far are encouraging and show dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.